Companies Abeona Therapeutics Inc
Abeona Therapeutics (ABEO): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Abeona Therapeutics Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,847,442FY2023
- $3,506,708FY2024
- $3,991,516FY2025
CEO total pay was $3,991,516 in fiscal 2025, up from $3,506,708 in fiscal 2024.
FY2025: salary $662,000 · bonus $533,333 · stock awards $2,472,698
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Vishwas Seshadri | $662,000 | $533,333 | $2,472,698 | — | $309,485 | — | $14,000 | $3,991,516 |
| President and Chief Executive Officer | ||||||||
| Joseph Vazzano | 475,903 | 235,333 | 836,400 | — | 173,229 | — | 14,000 | 1,734,865 |
| Chief Financial Officer | ||||||||
| Brendan O’Malley | 456,435 | 150,000 | 600,000 | — | 163,491 | — | 14,000 | 1,383,926 |
| Chief Legal Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Vishwas Seshadri | $3,991,516 | $3,506,708 | $2,847,442 | ↑ +484,808 |
| Joseph Vazzano | 1,734,865 | 1,633,999 | 1,492,742 | ↑ +100,866 |
| Brendan O’Malley | 1,383,926 | 1,270,436 | 1,169,287 | ↑ +113,490 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation programs are designed to attract, motivate, and retain our management talent, including the named executive officers, and to reward them for strong Company performance and successful execution of our key business plans and strategies.
| CEO STI target (% of salary) | NaN% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford, a unit of Aon plc |
| Clawback policy | true |
| Anti-hedging | Under the insider trading policy, directors, executive officers, and employees generally may not engage in short-term, speculative trading in Company stock, such as entering into short sales, buying, selling or writing puts or calls, or engaging in hedging or other derivative transactions. |
| Anti-pledging | Under the insider trading policy, directors, executive officers, and employees generally may not hold Company stock in a margin account or pledge Company stock as collateral for a loan. |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Joseph Vazzano | RSA | 2022-07-02 | — | — | 12,000 | — | — |
Vehicle mix — grant-date fair value by award type
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Joseph Vazzano | RSU | 2,000 | — | $10,540 |
| Joseph Vazzano | RSU | 3,000 | — | 15,810 |
| Vishwas Seshadri | RSU | 13,333 | — | 70,265 |
| Joseph Vazzano | RSU | 18,186 | — | 95,840 |
| Joseph Vazzano | RSU | 30,301 | — | 159,685 |
| Vishwas Seshadri | RSU | 38,800 | — | 204,476 |
| Joseph Vazzano | RSU | 47,303 | — | 249,285 |
| Joseph Vazzano | RSU | 68,460 | — | 360,784 |
| Vishwas Seshadri | RSU | 103,467 | — | 545,269 |
| Vishwas Seshadri | RSU | 112,276 | — | 591,695 |
| Joseph Vazzano | RSU | 115,607 | — | 609,249 |
| Vishwas Seshadri | RSU | 144,509 | — | 761,562 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Leila Alland, M.DIndependent · Compensation · Science and Technology | $90,000 | $200,000 | — | — | $0 | $290,000 |
| Mark J. AlvinoIndependent · Audit · Compensation (Chair) | 85,000 | 200,000 | — | — | 0 | 285,000 |
| Michael AmorosoIndependent · Nominating and Corporate Governance | 85,000 | 200,000 | — | — | 0 | 285,000 |
| Faith L. CharlesIndependent · Compensation · Nominating and Corporate Governance (Chair) · Science and Technology | 72,500 | 200,000 | — | — | 0 | 272,500 |
| Donald A. WuchterlIndependent · Audit · Nominating and Corporate Governance | 67,500 | 200,000 | — | — | 0 | 267,500 |
| Eric Crombez, M.DIndependent · Science and Technology | 57,500 | 200,000 | — | — | 0 | 257,500 |
| Bernhardt G. Zeiher, M.DIndependent · Audit · Science and Technology | 57,500 | 200,000 | — | — | 0 | 257,500 |
| Christine SilversteinIndependent · Not standing for re-election | 50,000 | 200,000 | — | — | 0 | 250,000 |
| Vishwas Seshadri, Ph.DEmployee director | — | — | — | — | — | 0 |
| Keith A. GoldanIndependent · Audit (Chair) · Newly elected | — | — | — | — | — | — |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $200,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 15,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $565,000 |
| Equity awards (grant-date value) | $1,600,000 |
| All other compensation | $0 |
| Total cost of the board | $2,165,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Abeona Therapeutics as a peer
Companies that benchmark against ABEO
1 company names ABEO as a compensation peer
- Savara IncSVRAFY2025
Each company listed discloses ABEO in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ABEO in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Abeona Therapeutics Inc | 2025 | Vishwas Seshadri | $662,000 | $2,472,698 | — | $309,485 | $3,991,516 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-12 | 23,300,653 | 4,511,866 | 1,916,542 | 83.78% | Passed |
| 2025 | 2025-05-19 | 25,777,223 | 1,552,881 | 105,031 | 94.32% | Passed |
| 2023 | 2023-05-17 | 6,436,890 | 282,439 | 36,768 | 95.8% | Passed |
| 2022 | 2022-08-17 | 1,260,149 | 371,509 | 24,144 | 77.23% | Passed |
| 2019 | 2019-05-28 | 30,603,677 | 635,820 | 319,261 | 97.96% | Passed |
| 2016 | 2016-05-12 | 18,638,144 | 116,972 | 19,163 | 99.38% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-12 | 83.78%a |
| 2025 | 2025-05-19 | 94.32%b |
| 2023 | 2023-05-17 | 95.8%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (20 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Vishwas Seshadri. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · page 12. As printed: 3,991,516. View filing ↗
- Section 01, Joseph Vazzano. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 1,734,865. View filing ↗
- Section 01, Brendan O’Malley. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 1,383,926. View filing ↗
- Section 03, Joseph Vazzano RSA. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Leila Alland, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 290,000. View filing ↗
- Section 08, Mark J. Alvino. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 285,000. View filing ↗
- Section 08, Michael Amoroso. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 285,000. View filing ↗
- Section 08, Faith L. Charles. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 272,500. View filing ↗
- Section 08, Donald A. Wuchterl. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 267,500. View filing ↗
- Section 08, Eric Crombez, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 257,500. View filing ↗
- Section 08, Bernhardt G. Zeiher, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 257,500. View filing ↗
- Section 08, Christine Silverstein. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 250,000. View filing ↗
- Section 08, Vishwas Seshadri, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Keith A. Goldan. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: —. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-12. Item 5.07 · say-on-pay result. As reported: 83.78% (votes for as printed: 23,300,653). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-19. Item 5.07 · say-on-pay result. As reported: 94.32% (votes for as printed: 25,777,223). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-05-17. Item 5.07 · say-on-pay result. As reported: 95.8% (votes for as printed: 6,436,890). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 565,000 + equity 1,600,000 + all other 0 = 2,165,000, summed across the director compensation table rows.
- Abeona Therapeutics Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Abeona Therapeutics Inc's own proxy. As printed: 3,991,516. View filing ↗